Advances of malignant pleural mesothelioma

doi:10.3760/cma.j.issn.1673-422X.2015.06.017

Abstract

Abstract: Malignant pleural mesothelioma (MPM) is a malignant cancer originated from pleural mesothelial cell. The diagnosis of MPM is based on biopsy of pleura and immunohistochemistry. The current treatment of MPM is multimodality therapy including surgery, radiotherapy, chemotherapy and immunotherapy. There are two major surgical procedures: extrapleural pneumonectomy and pleurectomy/decortication. The main of radiotherapy is threedimensional conformal radiotherapy. Cisplatinum combined with pemetrexed is the firstline chemotherapy for the patients with MPM. The principal targets for immunotherapy include regulatory T cells, cytotoxic T lymphocyte associated antigen 4 and PD 1.

Key words: Mesothelioma, Therapy, Immune system, Hematology

Wu Xinshu, Zhao Xiaogang, Wu Licun, Cong Bo. Advances of malignant pleural mesothelioma[J]. Journal of International Oncology, 2015, 42(6): 462-465.

References

［1］ Cihan YB, Ozturk A, Arslan A, et al. ERCC1 as a biological marker guiding management in malignant pleural mesothelioma［J］. Asian Pac J Cancer Prev, 2014, 15(10): 4117-4123. ［2］ Neumann V, Loseke S, Nowak D, et al. Malignant pleural mesothelioma: incidence, etiology, diagnosis, treatment, and occupational health［J］. Dtsch Arztebl Int, 2013, 110(18): 319-326. ［3］ Acton V. Preventing pleural mesothelioma in patients with recognizable asbestosrelated pleural plaques［J］. J Thorac Cardiovasc Surg, 2014, 148(4): 1763. ［4］ Linton A, Pavlakis N, O′Connell R, et al. Factors associated with survival in a large series of patients with malignant pleural mesothelioma in New South Wales［J］. Br J Cancer, 2014, 111(9): 1860-1869. ［5］ Kanbay A, Ozer SZ, Tutar N, et al. Nonasbestosrelated malignant pleural mesothelioma［J］. Intern Med, 2014, 53(17): 1977-1979. ［6］ MenendezNavarro A, Lopez RC. Asbestosrelated occupational cancers compensated under the Spanish National Insurance System, 1978—2011［J］. Int J Occup Environ Health, 2014, 21(1): 31-39. ［7］ Husain AN, Colby T, Ordonez N, et al. Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group［J］. Arch Pathol Lab Med, 2013, 137(5): 647-667. ［8］ Szulkin A, Otvs R, Hillerdal CO, et al. Characterization and drug sensitivity profiling of primary malignant mesothelioma cells from pleural effusions［J］. BMC Cancer, 2014, 14: 709. ［9］ Kao SC, Klebe S, Henderson DW, et al. Low calretinin expression and high neutrophiltolymphocyte ratio are poor prognostic factors in patients with malignant mesothelioma undergoing extrapleural pneumonectomy［J］. J Thorac Oncol, 2011, 6(11): 1923-1929. ［10］ Klebe S, Brownlee NA, Mahar A, et al. Sarcomatoid mesothelioma: a clinicalpathologic correlation of 326 cases［J］. Mod Pathol, 2010, 23(3): 470-479. ［11］ Takeshima Y, Amatya VJ, Kushitani K, et al. Value of immunohistochemistry in the differential diagnosis of pleural sarcomatoid mesothelioma from lung sarcomatoid carcinoma［J］. Histopathology, 2009, 54(6): 667-676. ［12］ Lovato A, Marioni G, Manzato E, et al. Elderly patients at higher risk of laryngeal carcinoma recurrence could be identified by a panel of two biomarkers (nm23 H1 and CD105) and pN+ status［J］. Eur Arch Otorhinolaryngol, 2014, In press. ［13］ Cristaudo A, Bonotti A, Simonini S, et al. Combined serum mesothelin and plasma osteopontin measurements in malignant pleural mesothelioma［J］. J Thorac Oncol, 2011, 6(9): 1587-1593. ［14］ Ostroff RM, Mehan MR, Stewart A, et al. Early detection of malignant pleural mesothelioma in asbestosexposed individuals with a noninvasive proteomicsbased surveillance tool［J］. PLoS One, 2012, 7(10): e46091. ［15］ Bayram M, Dongel I, Akbas A, et al. Serum biomarkers in patients with mesothelioma and pleural plaques and healthy subjects exposed to naturally occurring asbestos［J］. Lung, 2014, 192(1): 197-203. ［16］ Rosenzweig KE. Current readings: improvements in intensitymodulated radiation therapy for malignant pleural mesothelioma［J］. Semin Thorac Cardiovasc Surg, 2013, 25(3): 245-250. ［17］ Papaspyros S, Papaspyros S. Surgical management of malignant pleural mesothelioma: impact of surgery on survival and quality of liferelation to chemotherapy, radiotherapy, and alternative therapies［J］. ISRN Surg, 2014, 2014: 817203. ［18］ Rena O, Casadio C. Extrapleural pneumonectomy for early stage malignant pleural mesothelioma: a harmful procedure［J］. Lung Cancer, 2012, 77(1): 151-155. ［19］ Martin JT, Zwischenberger BA, Fabian T. Malignant pleural mesothelioma: treatment options and novel therapies［J］. J Cancer Ther, 2014, 5(1): 60-66. ［20］ Opitz I. Management of malignant pleural mesotheliomathe European experience［J］. J Thorac Dis, 2014, 6 Suppl 2: S238-252. ［21］ Cho BC, Feld R, Leighl N, et al. A feasibility study evaluating surgery for mesothelioma after radiation therapy: the "SMART″ approach for resectable malignant pleural mesothelioma［J］. J Thorac Oncol, 2014, 9(3): 397-402. ［22］ Van Schil PE, Opitz I, Weder W, et al. Multimodal management of malignant pleural mesothelioma: where are we today?［J］. Eur Respir J, 2014, 44(3): 754-764. ［23］ Nuvoli B, Santoro R, Catalani S, et al. Cellfood induces apoptosis in human mesothelioma and colorectal cancer cells by modulating p53, c-myc and pAkt signaling pathways［J］. J Exp Clin Cancer Res, 2014, 33: 24. ［24］ Anraku M, Tagawa T, Wu L, et al. Synergistic antitumor effects of regulatory T cell blockade combined with pemetrexed in murine malignant mesothelioma［J］. J Immunol, 2010, 185(2): 956-966. ［25］ Wu L, Yun Z, Tagawa T, et al. Tumor cell repopulation between cycles of chemotherapy is inhibited by regulatory T cell depletion in a murine mesothelioma model［J］. J Thorac Oncol, 2011, 6(9): 1578-1586. ［26］ Xu P, Chen H, Chen YJ, et al. Expression of PD-1/PD-L1 in peripheral blood mononuclear cells in lung cancer patients and its biological significance［J］. Zhonghua Zhong Liu Za Zhi, 2013, 35(12): 910-913. ［27］ Wei T, Zhang J, Wu Y, et al. Expression levels of coinhibitory molecules CTLA4, LAG3, PD1 and CD39 on CD4+ T cells correlate with progression of nonsmall cell lung cancer［J］. Zhonghua Zhong Liu Za Zhi, 2014, 36(6): 424-429. ［28］ Wu L C, Yun Z H, Tagawa T, et al. CTLA4 blockade expands infiltrating T cells and inhibits cancer cell repopulation during the intervals of chemotherapy in murine mesothelioma［J］. Mol Cancer Ther, 2012, 11(8): 1809-1819.

[1]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei. Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study [J]. Journal of International Oncology, 2024, 51(6): 326-331.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Zhang Baihong, Yue Hongyun. Advances in anti-tumor drugs with new mechanisms of action [J]. Journal of International Oncology, 2024, 51(6): 354-358.
[4]	Xu Fenglin, Wu Gang. Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma [J]. Journal of International Oncology, 2024, 51(6): 359-363.
[5]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[6]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[7]	Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua. Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy [J]. Journal of International Oncology, 2024, 51(5): 257-266.
[8]	Wang Peixin, Zhao Jun, Xu Shihong, Jiang Zhaoyang, Wang Xiaoqiang, Yang Hongjuan. Progress of ferroptosis-related mechanisms in osteosarcoma [J]. Journal of International Oncology, 2024, 51(5): 308-311.
[9]	Yang Hao, Shi Guidong, Zhang Chengcheng, Zhang Yue, Zhang Liwen, Fu Maoyong. Comparison of efficacy and safety between sintilimab and tislelizumab in neoadjuvant therapy for advanced esophageal squamous cell carcinoma [J]. Journal of International Oncology, 2024, 51(4): 210-216.
[10]	Sa Qiang, Xu Hangcheng, Wang Jiayu. Advances in immunotherapy for breast cancer [J]. Journal of International Oncology, 2024, 51(4): 227-234.
[11]	Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong. Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer [J]. Journal of International Oncology, 2024, 51(4): 235-238.
[12]	Sun Weiwei, Yao Xuemin, Wang Pengjian, Wang Jing, Jia Jinghao. Exploration of prognostic factors and nomogram construction for advanced non-small cell lung cancer treated with immunotherapy based on hematologic indexes [J]. Journal of International Oncology, 2024, 51(3): 143-150.
[13]	Qian Xiaotao, Shi Ziyi, Hu Ge. A real-world clinical study of immunocheckpoint inhibitor maintenance therapy after radical radiotherapy and chemotherapy in stage Ⅲ-ⅣA esophageal squamous cell carcinoma [J]. Journal of International Oncology, 2024, 51(3): 151-156.
[14]	Li Shuyue, Ma Chenying, Zhou Juying, Xu Xiaoting, Qin Songbing. Progress of radiotherapy in oligometastatic non-small cell lung cancer [J]. Journal of International Oncology, 2024, 51(3): 170-174.
[15]	Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan. Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer [J]. Journal of International Oncology, 2024, 51(3): 175-180.